Skip to main content

Advertisement

SpringerLink
Log in

Does the method of obtaining glycemic control influence cardiovascular outcomes?

  • Clinical Trials Report
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Buse JB: Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods. Am J Cardiol 2007, 99:S21–S33.

    Article  Google Scholar 

  2. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.

    Article  Google Scholar 

  3. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.

    Article  Google Scholar 

  4. Patel A; ADVANCE Collaborative Group; MacMahon S, Chalmers J, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829–840.

    Article  PubMed  CAS  Google Scholar 

  5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580–591.

    Article  PubMed  CAS  Google Scholar 

  6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854–865.

  7. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.

    Article  PubMed  CAS  Google Scholar 

  8. Rosen CJ: The rosiglitazone story—lessons from an FDA advisory committee meeting. N Engl J Med 2007, 357:844–846.

    Article  PubMed  CAS  Google Scholar 

  9. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189–1195.

    Article  PubMed  CAS  Google Scholar 

  10. Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129–1136.

    Article  PubMed  CAS  Google Scholar 

  11. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180–1188.

    Article  PubMed  CAS  Google Scholar 

  12. Klepzig H, Kober G, Matter C, et al.: Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999, 20:439–446.

    Article  PubMed  CAS  Google Scholar 

  13. Goldberg RB, Kendall DM, Deeg MA, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547–1554.

    Article  PubMed  CAS  Google Scholar 

  14. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.

    Article  PubMed  CAS  Google Scholar 

  15. Haffner SM, Greenberg AS, Weston WM, et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679–684.

    Article  PubMed  CAS  Google Scholar 

  16. Pistrosch F, Passauer J, Fischer S, et al.: In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004, 27:484–490.

    Article  PubMed  CAS  Google Scholar 

  17. Stocker DJ, Taylor AJ, Langley RW, et al.: A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007, 153:445.e1–445.e6.

    Article  Google Scholar 

  18. Diamond GA, Gax L, Kaul S: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578–581.

    PubMed  Google Scholar 

  19. Steg PG, Marre M: Does PERISCOPE provide a new perspective on diabetic treatment? JAMA 2008, 299:1603–1604.

    Article  PubMed  CAS  Google Scholar 

  20. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29–38.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Anthony L. McCall
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCall, A.L. Does the method of obtaining glycemic control influence cardiovascular outcomes?. Curr Diab Rep 8, 341–344 (2008). https://doi.org/10.1007/s11892-008-0060-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-008-0060-8

Keywords

Search

Navigation